Formosa Pharmaceuticals Teams Up with Eyenovia to Create Innovative Solutions

Formosa Pharmaceuticals (6838.TWO) has entered into an exciting collaboration with Eyenovia, Inc. (NASDAQ: EYEN) to develop innovative ophthalmic products. This groundbreaking agreement brings together Formosa’s APNT™ formulation platform and Eyenovia’s Optejet® delivery system in a powerful combination that promises to drive revolutionary advancements in eye care.

Optejet®, Eyenovia’s innovative delivery platform for ocular therapeutics, is here to revolutionize the way you care for your eyes. Utilizing Microdose Array Print (MAP™) technology, Optejet® delivers just 6-8 microliters of drug product, making it significantly more precise than conventional eyedroppers. This incredibly low volume reduces the risk of overdosing and unnecessary drug exposure, while the rapid and gentle action ensures efficient and comfortable delivery to the ocular surface. So, trust Optejet® for your ocular health – because your eyes deserve the best.

Formosa’s unique APNT™ formulation platform helps to revolutionize the delivery of active pharmaceutical ingredients through its mild yet effective particle size reduction technique. This cutting-edge technology is optimized for topical, oral, or inhaler administration routes and boasts a high level of purity, uniformity, and stability. With this platform, even drugs with poor solubility or immense potency can now be effectively delivered and penetrate target tissues with ease.

Eyenovia is thrilled to announce a development collaboration with Formosa that will bring the many benefits of Optejet® to the ophthalmic market. With improved patient compliance and the ability to achieve therapeutic doses of medication with far less stress on the ocular surface than other forms of administration, this partnership will not only expand the potential of Optejet® but also open up new and large market indications for Eyenovia’s own development pipeline with the help of Formosa’s proven ophthalmic formulation expertise and APNT™ formulation platform. Both parties look forward to a successful and long-term partnership.

Formosa Pharmaceuticals is thrilled to embark on this exciting collaboration with Eyenovia to explore new heights in ophthalmology. By combining our cutting-edge proprietary technologies, APNT™ and Optejet®, we have the potential to unlock a broad range of ophthalmic therapeutics and applications. We look forward to quickly launching this collaboration and unlocking its potential to make a real difference in this field.

About Formosa Pharmaceuticals, Inc.

Formosa Pharmaceuticals, Inc. (6838.TWO) is a pioneering biotechnology company that is on the cutting edge of ophthalmology and oncology research. Their lead program, APP13007, is a ground-breaking corticosteroid nanosuspension developed through their innovative APNT™ technology and has already achieved success in Phase 3 trials. With its submission to the FDA later this year, APP13007 could revolutionize the treatment of inflammation and pain following ocular surgery.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is revolutionizing ophthalmology with its cutting-edge microdose array print (MAPTM) technology. The company is dedicated to the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. Topping the list of advanced programs is MydCombi, a groundbreaking combination of tropicamide and phenylephrine that enables rapid, effective in-office pupil dilation for routine eye exams. With Eyenovia’s pioneering technology, the future of ophthalmology looks brighter than ever.

Leave a Comment